Higher motor activity in schizophrenia patients treated with olanzapine versus risperidone

Journal of Clinical Psychopharmacology

Volumn 30, Issue 2, 2010, Pages 181-184

  Walther, Sebastian ^a   Horn, Helge ^a   Razavi, Nadja ^a   Koschorke, Philipp ^a   Wopfner, Alexander ^a   Müller, Thomas J ^a   Strik, Werner ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Actigraphy; Quantitative motor activity; Treatment effects

Indexed keywords

CHLORPROMAZINE; OLANZAPINE; RISPERIDONE;

ACTIMETRY; ADULT; ARTICLE; BODY MOVEMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; FEMALE; HOSPITAL PATIENT; HUMAN; IMMOBILIZATION; MALE; MOTOR ACTIVITY; MOTOR RETARDATION; PARKINSONISM; PHYSICAL ACTIVITY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ADULT; AMBULATORY CARE; BENZODIAZEPINES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77952130941     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181d2ef6f     Document Type: Article

References (30)

1. Morrens M, Hulstijn W, Sabbe B. Psychomotor slowing in schizophrenia. Schizophr Bull. 2007 33: 1038-1053.
2. Kane JM, Sharif ZA. Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry. 2008 69(suppl 1): 18-31.
3. Lieberman. JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209-1223. (Pubitemid 41345943)
4. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009 166: 152-163.
5. Lindenmayer JP, Czobor P, Volavka J, et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry. 2004 65: 551-556.
6. Feldman PD, Kaiser CJ, Kennedy JS, et al. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. J Clin Psychiatry. 2003 64: 998-1004.
7. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970 212: 11-19.
8. MeEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006 163: 600-610.
9. Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev. 2006; (2): CD005237.
10. Ritsner M, Gibel A, Perelroyzen G, et al. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol. 2004; 24: 582-591. (Pubitemid 39518652)
11. MeGrath BM, Tempier RP. Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey. Pharmacopsychiatry. 2005 38: 147-157.
12. Artaloytia JF, Arango C, Lahti A, et al. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry. 2006; 163: 488-493. (Pubitemid 44469392)
13. Kiang M, Daskalakis ZJ, Christensen BK, et al. Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. J Psychiatry Neurosci. 2003; 28: 293-299. (Pubitemid 37153437)
14. Morrens M, Wezenberg E, Verkes RJ, et al. Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration. J Clin Psychopharmacol. 2007; 27: 15-21. (Pubitemid 46105758)
15. Putzhammer A, Heindl B, Broll K, et al. Spatial and temporal parameters of gait disturbances in schizophrenic patients. Schizophr Res. 2004; 69: 159-166. (Pubitemid 38721415)
16. Putzhammer A, Perfahl M, Pfeiff L, et al. Performance of diadochokinetic movements in schizophrenic patients. Schizophr Res. 2005; 79: 271-280. (Pubitemid 41457267)
17. Morrens M, Hulstijn W, Sabbe B. The effects of atypical and conventional antipsychotics on reduced processing speed and psychomotor slowing in schizophrenia: a cross-sectional exploratory study. Clin Ther. 2008; 30: 684-692. (Pubitemid 351680498)
18. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000 57: 249-258.
19. Fitzgerald PB, Brown TL, Daskalakis ZJ, et al. A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia. Psychopharmacology (Berl). 2002; 162: 74-81. (Pubitemid 34639560)
20. Teicher MH. Actigraphy and motion analysis: new tools for psychiatry. Harv Rev Psychiatry. 1995 3: 18-35.
21. Janno S, Holi MM, Tuisku K, et al. Actometry and Barnes Akathisia Rating Scale in neuroleptic-induced akathisia. Eur Neuropsychopharmacol. 2005; 15: 39-41. (Pubitemid 39574398)
22. Janno S, Holi MM, Tuisku K, et al. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol. 2005; 5: 5. (Pubitemid 41418222)
23. Walther S, Horn H, Razavi N, et al. Quantitative motor activity differentiates schizophrenia subtypes. Neuropsychobiology. 2009 60: 80-86.
24. Walther S, Koschorke P, Horn H, et al. Objectively measured motor activity in schizophrenia challenges the validity of expert ratings. Psychiatry Res. 2009 169: 187-190.
25. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003 64: 663-667.
26. Middelkoop HA, van Dam EM, Smilde-van den Doel DA, et al. 45-hour continuous quintuple-site actimetry: relations between trunk and limb movements and effects of circadian sleep-wake rhythmicity. Psychophysiology. 1997 34: 199-203.
27. Walther S, Horn H, Koschorke P, et al. Increased motor activity in cycloid psychosis compared to schizophrenia. World J Biol Psychiatry. 2009 10: 746-751.
28. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13: 261-276. (Pubitemid 18039085)
29. Villari V, Rocca P, Fonzo V, et al. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry. 2008 32: 405-413.
30. Martenyi F, Metcalfe S, Schausberger B, et al. An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms. J Clin Psychiatry. 2001 62(suppl 2): 25-27.